Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Organisation › Details

MeiraGTx (Group)

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. *

 

Period Start 2018-10-05 existent
Product Industry gene therapy
Persons Person Forbes, Alexandria (MeiraGTx 201810 CEO)
  Person 2 Breedis, Katherine (MeiraGTx 201810– CFO before Stifel Nicolaus + Pfizer + Eli Lilly + Schroder + Goldman Sachs + Citi)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 92 Britannia Walk
  City N1 7NQ London
    Address record changed: 2018-10-10
     
Basic data Employees n. a.
  Currency USD
  Profit -82,865,874 (2018-12-31)
  Cash 68,080,175 (2018-12-31)
     
    * Document for �About Section�: MeiraGTx Holdings plc. (10/9/18). "Press Release: MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson’s Disease". London & New York.
     
   
Record changed: 2019-04-01

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for MeiraGTx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top